Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

6 treatments under study, led by Pembrolizumab Vorinostat

Research Leaders

7 sponsors active, led by ERA-NET

Related Conditions

Often studied with 11 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 4 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

4Total
Phase 2 (3)
Phase 3 (1)

Trial Status

Completed2
Unknown1
Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (4)

Showing 4 of 4 trials
NCT07435376Phase 2Recruiting

Intra-lesional Tumor Boost for Bulky Cervical Cancer

NCT04357873Phase 2Completed

Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations

NCT02765919Phase 3CompletedPrimary

A Randomised Controlled Trial Between Two Different HDR Brachytherapy Schedule in Locally Advanced Carcinoma of Uterine Cervix

NCT02879214Phase 2UnknownPrimary

Simultaneously Integrated Dose Escalation for Locally Advanced Cervical Cancer

Showing all 4 trials

Research Network

Common Treatments

  • Pembrolizumab Vorinostat1
  • Simultaneous Boost Along With Chemo1
  • High Dose Rate Brachytherapy1
  • Hdr Brachytherapy Of 9 Gy In 2 Fractions1
  • Intralesional Boost Imrt1

Active Sponsors

  • ERA-NET1
  • Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh1
  • UNICANCER1
  • Merck Sharp & Dohme LLC1
  • Fondation ARC1

Top Investigators

Related Conditions

  • Anal Cancer1
  • Head And Neck Squamous Cell Carcinoma1
  • Cervical Cancer1
  • Squamous Cell Carcinoma Of Penis1
  • Squamous Cell Lung Cancer1

Activity Timeline